/

BDRX

Biodexa Pharmaceuticals plcClosed

0.3502−0.03 −8.61%USD

NasdaqCM · as of Oct 13, 16:00 ET · 15m delayAfter hours 0.5044 +44.03%

Open

0.4169

Prev close

0.3832

Day range

0.33710.4199

52-week range

0.337144.70

Volume

13.84M3.65×

Mkt cap

771.92K

P/E ttm

0.01

Fwd P/E

—

EPS ttm

63.74

Div yield

0.00%

Earnings

—

From 52w high

−99.22%

Price Chart

Yahoo Finance · delayed

BDRXOct 13, 2026O 0.4170H 0.4200L 0.3370C 0.3500−0.0330 (−8.62%)Vol 13.87M

SMA 500.9653
SMA 2003.9098

1Y change −99.11% since Oct 13, 2025 close539 bars loadedTimes in America/New_YorkDraw from the left toolbar · click a drawing to edit · right-click for alerts and export

BDRX Biodexa Pharmaceuticals plc · Last Guard Finance

DES

Key Statistics

Yahoo Finance

Performance

1 week: −41.18%
1 month: −73.08%
3 months: −84.58%
6 months: −89.23%
Year to date: −96.92%
1 year: −99.11%

Valuation & ownership

Market cap: 771.92K
Enterprise value: −2.97M
P/E (ttm): 0.01
Forward P/E: —
PEG ratio: —
Price / book: 0.02
Price / sales (ttm): —
EV / EBITDA: 0.34
EPS (ttm): 63.74
EPS (forward): 0.000000
Beta (5y monthly): 1.28
Dividend yield: 0.00%
Payout ratio: 0.00%
Shares outstanding: 2.20M
Float: 684.07K
Short % of float: 0.83%
Short ratio (days): 0.00
Held by insiders: 0.00%
Held by institutions: 0.37%
Avg volume (3m): 3.79M
50-day average: 0.9867
200-day average: 3.98
52-week change: −99.11%
S&P 500 52-week: +17.03%

Technicals (daily)

RSI (14): oversold 26.0
vs 50-day SMA: −63.74%
vs 200-day SMA: −91.05%
50 / 200-day trend: ▼ 50 below 200
MACD vs signal: ▼ below
ATR (14) % of price: 31.00%
Realised vol (20d, ann.): 134.9%
From 52-week high: −99.22%
From 52-week low: +3.86%

ANR

Analyst Consensus

1 analysts

Consensus

—

Mean target

8.93

+2,450.72% implied

Low 8.93Median 8.93High 8.93

Recommendation trend

Now0 / 0 / 0

Buy / hold / sell counts

Financial Snapshot

Full statements →trailing twelve months

DES

About Biodexa Pharmaceuticals plc

Yahoo Finance profile

Biodexa Pharmaceuticals Plc, a clinical stage biopharmaceutical company, focuses on developing a pipeline of products for the treatment of familial adenomatous polyposis, non-muscle invasive bladder cancer, and Type 1 diabetes and rare/orphan brain cancer. Its lead product candidate, Tolimidone, is a selective activator of the lyn kinase enzyme, currently under Phase II studies for the treatment of Type 1 diabetes. The company is also developing MTX110, which is currently in Phase I studies for the treatment of recurrent glioblastoma, diffuse midline glioma, and medulloblastoma; and MTX240, for the treatment of gastrointestinal stromal tumors. In addition, the company offers drug delivery platforms, such as Q-Sphera, a polymer microsphere microtechnology used for sustained release therapeutics; MidaSolve, nanotechnology used to dissolve insoluble drugs so that they can be administered in liquid form directly and locally into tumours; and MidaCore, a gold nanoparticle used for targeting sites of disease. It has collaboration agreements with Janssen and Melior. The company was formerly known as Midatech Pharma plc and changed its name to Biodexa Pharmaceuticals Plc in March 2023. Biodexa Pharmaceuticals Plc was founded in 2000 and is headquartered in Cardiff, the United Kingdom.

Sector: Healthcare
Industry: Biotechnology
Employees: 11
Headquarters: Cardiff, United Kingdom
Website: biodexapharma.com
Officers: Mr. Stephen Anthony Stamp CEO & Director
Ms. Fiona Mary Sharp

SEAS

Seasonality · BDRX

2015–2026 · monthly returns

Strongest month Feb +24.46%Weakest month Dec −23.79%Averages use completed years only. Past seasonality doesn't predict future returns.

Year	Jan	Feb	Mar	Apr	May	Jun	Jul	Aug	Sep	Oct	Nov	Dec	Year
2026	-22.0	-39.0	-42.8	1.6	10.5	-16.1	-54.6	-38.5	-19.2	-46.6			−96.9%
2025	8.8	-24.4	-60.4	10.6	-26.0	-19.9	-9.2	-29.4	20.0	-4.8	-28.4	-49.9	−94.4%
2024	-39.9	-21.1	27.6	-6.8	-36.2	-7.1	-23.0	-20.3	-48.7	-12.8	-8.6	-27.9	−94.0%
2023	-28.9	-25.7	-81.3	-42.1	-62.8	-17.9	-1.3	46.6	-37.5	-24.2	-4.2	-26.0	−99.1%
2022	-3.8	-2.9	-10.3	-26.1	-3.7	-13.7	21.3	13.0	-49.7	4.3	-18.0	-38.1	−81.2%
2021	13.9	7.0	-6.6	-7.0	-3.5	8.9	-10.6	-1.6	-4.9	-2.3	-14.1	-28.1	−43.9%
2020	5.1	-28.9	-30.1	63.9	-57.6	10.0	48.4	13.7	-22.0	-0.6	-0.6	4.5	−45.7%
2019	-21.9	354.5	-33.3	-49.6	-20.2	-2.4	6.9	-19.5	-0.8	-24.4	-27.5	2.2	−55.5%
2018	27.7	-2.8	-20.2	-12.0	-0.5	-5.6	-9.5	38.4	-32.6	-27.3	-36.2	-42.2	−81.5%
2017	14.1	-9.2	-8.7	6.1	0.7	-7.5	3.1	-12.9	-33.1	-8.4	-14.8	-30.7	−69.6%
2016	-4.1	-1.9	-11.6	12.9	-17.3	-25.0	-1.5	45.7	-22.0	-13.6	2.9	-1.8	−43.1%
2015													—

BDRX

Price Chart

Keyboard shortcuts & functions

Anywhere

Command line

Charts (click the chart first)

Function codes

BDRX

Price Chart

Key Statistics

Performance

Valuation & ownership

Technicals (daily)

Analyst Consensus

Financial Snapshot

About Biodexa Pharmaceuticals plc

Seasonality · BDRX

Insider Activity · BDRX

Congress Trades · BDRX

Investors Holding BDRX

Investors Holding BDRX

Congress Trades · BDRX

Insider Activity · BDRX

Seasonality · BDRX

Key Statistics

Performance

Valuation & ownership

Technicals (daily)

Analyst Consensus

Financial Snapshot

About Biodexa Pharmaceuticals plc

Earnings & Dividends

News